News
-
-
COMMUNIQUÉ DE PRESSE
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Telomir-1 treatment shows promising results in reversing aging hallmarks in a rare genetic disorder. Findings include restored gene control, extended telomere length, muscle and weight recovery, reduced oxidative stress, and 100% survival -
COMMUNIQUÉ DE PRESSE
Orogen Royalties Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General and Special Meeting of Shareholders
Orogen Royalties Inc. announces annual general meeting for shareholders to vote on proposed arrangement with Triple Flag. Shareholder support recommended. Contact Laurel Hill Advisory Group for assistance -
-
COMMUNIQUÉ DE PRESSE
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
VeonGen Therapeutics (formerly ViGeneron) announces FDA Rare Pediatric Disease Designation and clinical progress for lead gene therapy VG801 in Stargardt Disease, advancing genetic medicine in ophthalmology and beyond -
COMMUNIQUÉ DE PRESSE
Brenmiller Energy CEO Provides Update On Milestones Powering Progress
Brenmiller Energy provides shareholder update highlighting strategic projects including the SolWinHy Project receiving €25 million in funding and the upcoming milestone with Tempo. The company explores opportunities in nuclear energy for AI and data centers -
-
-
-
COMMUNIQUÉ DE PRESSE
Alstom S.A. : Assemblée générale annuelle mixte du 10 juillet 2025 - Modalités de mise à disposition des documents préparatoires
La Société ALSTOM annonce son Assemblée Générale Mixte du 10 juillet 2025 et la mise à disposition des documents préparatoires, incluant les modalités de participation et de vote
